• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » InVentiv Expands REMS Business with ParagonRx Acquisition

InVentiv Expands REMS Business with ParagonRx Acquisition

January 7, 2010
CenterWatch Staff

Banking on the growing demand for risk evaluation and mitigation strategy services (REMS), New Jersey-based inVentiv Health acquired REMS consulting company ParagonRx for an undisclosed sum in a deal that was finalized December 31.

inVentiv, which provides marketing, communications and staffing to the pharmaceutical industry, launched its REMS business last August in response to a growing demand for these types of services to meet U.S. Food and Drug Administration (FDA) regulations. The FDA requires pharma companies to submit a  REMS for selected products. Companies failing to submit a suitable REMS may experience approval delays and other roadblocks.

"Driving safe and appropriate use of medicine and managing potential risks are key priorities for inVentiv's clients, and thus, we recently launched an integrated REMS offering to support these growing needs," said Blane Walter, chief executive officer of inVentiv Health. "Today we are significantly strengthening our REMS capabilities with the acquisition of ParagonRx, unquestionably one of the industry's top experts in risk mitigation. Their extensive experience in consultative REMS and safety services is an ideal complement to inVentiv Health's broad array of risk communications and REMS implementation services. The resulting combination will enable inVentiv to deliver a truly comprehensive REMS and risk management solution to our clients on a global basis through a single point of contact."

Based in Wilmington, Del., ParagonRx was founded in 2001 by former DuPont executive Jeffrey Fetterman and Gary Slatko, M.D., also a former pharma executive.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing